Pfizer CEO objects to US call to waive intellectual property rights for Corona vaccines | latest news


Albert Burla, CEO of Pfizer, warned Friday, May 7, that waiving intellectual property for Coronavirus vaccines – a proposal President Joe Biden has just approved – would trigger a global race for raw materials and that in his role threatens the safe and effective manufacture of vaccine doses.

The Biden administration said Wednesday it supports the limited waiver of intellectual property rules in the service of expanding vaccine distribution to low-income countries currently experiencing an epidemic.

But Burla, whose company produces one of the three vaccines approved for emergency use in the United States, said he believed “categorically” that the waiver proposal “would create more problems.”

“At the moment, the infrastructure is not a bottleneck for us to manufacture faster, the constraint is the scarcity of raw materials needed to produce our vaccine,” he said.

Burla said the Pfizer vaccine requires 280 different substances and ingredients sourced from 19 countries around the world.

Without intellectual property protection, he said, entities with much less experience with Pfizer manufacturing vaccines would start competing for the same ingredients.

He pointed out that, “At the present time, almost every gram of raw materials is shipped immediately to our manufacturing facilities and is immediately and reliably converted into vaccines that are immediately shipped all over the world.”

He predicted that the proposed concession “threatens to disrupt the flow of raw materials.”


Please enter your comment!
Please enter your name here